[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pseudomonas-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pseudomonas-infections":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100572861","antimicrobial-therapy-for-difficult-to-treat-pseudomonas-aeruginosa-100572861",false,"NCT06738771","Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa","Antimicrobial Therapy for Infections Due to Pseudomonas Aeruginosa With Difficult-to-treat Resistance: a Real-world, Prospective, Multicenter Cohort Study","ADDICT","Inclusion Criteria:\n\n* All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection\n\nExclusion Criteria:\n\n* Cystic fibrosis\n* P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic therapy\n* Protected person (under guardianship or curatorship)\n* Persons under court protection\n* Persons deprived of liberty\n* Opposition expressed for participation in the study","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam\u002Fbeta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.",[25,26,27,28,29,30],"Pseudomonas Infections","Pseudomonas Aeruginosa","Prognosis","Drug Resistance, Multiple, Bacterial","Antibacterial Agents","Beta-lactam Antibiotics","RECRUITING","2026-04-29",{"date":34,"type":35},"2026-04-30","ACTUAL",{"date":37,"type":35},"2025-03-11",{"date":39,"type":21},"2027-01",{"name":41,"class":42},"Centre Hospitalier Régional d'Orléans","OTHER",48,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100597314","monotherapy-vs-combination-therapy-for-bone-infections-caused-by-pseudomonas-aeruginosa-100597314","NCT07056881","Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa","Inclusion Criteria:\n\n* Adult patients (≥18 years old)\n* Diagnosis of osteitis or osteomyelitis due to Pseudomonas aeruginosa\n* Isolation of Pseudomonas aeruginosa from at least one deep, sterile sample (e.g., bone biopsy, joint aspiration)\n* Imaging findings consistent with osteomyelitis (MRI, CT scan, or X-ray)\n\nExclusion Criteria:\n\n* No isolation of Pseudomonas aeruginosa\n* No imaging evidence suggestive of osteomyelitis\n* Patients under 18 years of age",{"count":51,"type":21},300,"This study looks at how well one antibiotic (monotherapy) works compared to two antibiotics (combination therapy) in treating bone infections caused by Pseudomonas aeruginosa. It includes 300 adult patients who had this type of infection confirmed by lab tests and medical imaging. The goal is to find out if using just one antibiotic is as effective as using two, while also looking at side effects, the need for more surgery, antibiotic resistance, and overall antibiotic use.",[54,25,26,55],"Osteomyelitis","Bacterial Infections","2025-06-30",{"date":58,"type":35},"2025-07-09",{"date":60,"type":35},"2025-04-11",{"date":62,"type":21},"2026-04-15",{"name":64,"class":42},"Centre Hospitalier de Saint-Denis",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":65},"100289166","monocyte-profiles-in-critically-ill-patients-with-pseudomonas-aeruginosa-sepsis-100289166","NCT03044223","Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis","Phenotypical Und Functional Characterization of Macrophages in Critically Ill Patients With Pseudomonas Aeruginosa Induced Sepsis","MIPSA","Inclusion Criteria:\n\n* age \\> 18 years\n* critically ill patients with sepsis\n* microbiologically proven infection with Pseudomonas aeruginosa\n\nExclusion Criteria:\n\n* life expectancy \\\u003C 24 hours\n* participation in other studies",true,"90 Years",{"count":77,"type":21},100,"The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.",[25,80,81,82,83,84,85,86,87],"Pseudomonas Septicemia","Pseudomonas; Pneumonia","Pseudomonal Bacteraemia","Pseudomonas Urinary Tract Infection","Pseudomonas Gastrointestinal Tract Infection","Sepsis","Sepsis, Severe","Critically Ill",[89,90,91,92,93,94,95],"pseudomonas aeruginosa","critically ill patient","sepsis","monocyte","macrophage","cytokine","severity of disease","2024-01-16",{"date":98,"type":35},"2024-01-17",{"date":100,"type":4},"2014-08",{"date":102,"type":21},"2026-12",{"name":104,"class":42},"University of Ulm"]